General Information

  • Very high risk of C. difficile colitis
  • QTc prolongation
  • Tendinopathy and rupture
  • Aortic dissection, aneurysm
  • CNS toxicity including confusion and psychosis
  • Opiate screen false positives
  • Hypo/hyperglycemia
  • Peripheral neuropathy
  • Thrombocytopenia
  • Strong CYP1A2 inhibitor and weak CYP3A4 inhibitor - Multiple interactions possible
  • QTc prolongation - Increased risk with other agents that prolong QTc
  • AVOID concomitant administration with antacids, multivitamin & mineral supplements. Space doses by 2 hours.
  • Increased risk of tendon rupture with concomitant use of corticosteroids.
  • Monitor INR with warfarin.

Appropriate use includes treatment of serious gram-negative infections when other antimicrobials are unsuitable due to resistance profile.

Oral bioavailability is 80-90% and oral route should be used if there is a functioning gastrointestinal tract.

Concentration: 100 mg/mL

Taste: Metallic taste

Not all strengths of oral liquids are listed nor be available on the CHEO Formulary

  • 250 mg
  • 500 mg
  • 750 mg

Tablets or capsules are preferred especially over an unpleasant tasting oral liquid.

Not all strengths of oral tablets/capsules are listed and they are not all available on the CHEO Formulary.